One-year survival in congenital heart defects rose steadily, even as gains slowed after 2007
A population-based analysis from the Paris Registry of Congenital Anomalies tracks how outcomes for congenital heart defects changed over three decades, and the pattern is unmistakable: survival improved, but the pace of progress eased over time. Among 5,898 cases collected between 1994 and 2024, 4,391 were live births, 1,361 ended in termination of pregnancy for fetal anomaly, and 146 were stillbirths. Overall one-year survival reached 91.0% with a 95% confidence interval of 90.1% to 91.8%. In isolated CHD, survival climbed to 95.0%, while severe isolated CHD still carried a much steeper mortality burden, with one-year survival at 84.0%.
The trajectory matters because congenital heart disease is not one condition but a spectrum of malformations with very different physiologic consequences. Some defects are hemodynamically modest and compatible with near-normal neonatal adaptation, while others drive early circulatory collapse, profound hypoxemia, or progressive heart failure in infancy. Improvements in fetal diagnosis, delivery planning, neonatal intensive care, and pediatric cardiac surgery likely all contributed to the upward survival curve. Yet the effect was not linear; the data show a change in slope around 2007 to 2009, after which the annual absolute gain became smaller.
A plateau did not appear. The curve simply became less steep.
Severe isolated disease still improved, but the calendar years tell a more restrained story
Temporal analysis showed significant improvement across the full cohort, with one-year survival rising over time and the annual absolute gain falling from about +0.5% early in the study period to about +0.2% in recent years. In isolated CHD, the same broad direction held, but gains again became smaller after roughly 2009. Severe isolated CHD also improved, with survival rising by +0.56% per year. Those numbers suggest that even the most serious isolated lesions benefited from advances in management, although the residual mortality remained substantial compared with the broader isolated group.
This is the bedside implication: children born with severe isolated defects are still living longer than they did decades ago, but the remaining gap is not trivial. The physiology of severe lesions leaves less room for error. A malformed outflow tract, a single-ventricle pathway, or a critical obstruction can trigger a chain of hypoperfusion and organ injury before definitive repair is possible. Better prenatal detection and planned referral to tertiary centers can shift that balance, but the disease burden does not disappear simply because outcomes improve across the population.
The registry design strengthens the observation. A population-based dataset avoids the selective lens of single-center surgical series, where referral patterns and case mix can distort survival estimates. Here, the long time horizon gives the trends clinical weight. It also shows a more complicated reality than a simple “better over time” narrative: progress continued, but each incremental gain became harder to secure.
Prenatal diagnosis was followed by fewer terminations in isolated and severe isolated lesions
Among pregnancies with a recorded prenatal diagnosis of CHD, termination of pregnancy for fetal anomaly declined in isolated CHD by −0.50% per year and in severe isolated CHD by −0.36% per year. Those declines occurred in parallel with improving survival, suggesting that counseling, expectant management, and confidence in postnatal treatment may all have changed over time. When survival becomes more realistic for families and clinicians, the decision-making around pregnancy continuation shifts as well.
The biological and clinical logic is straightforward. Prenatal diagnosis of CHD identifies lesions before birth, allowing families to plan delivery in specialized centers and allowing teams to anticipate prostaglandin use, urgent catheter-based intervention, or neonatal surgery. As fetal cardiology and neonatal cardiac care matured, the perceived prognosis of some lesions likely improved, especially for defects that are severe but anatomically manageable. In that setting, lower termination rates may reflect both improved counseling and the growing expectation that repair or palliation can offer meaningful survival.
These data do not imply a uniform shift across all congenital defects. The report separates isolated from non-isolated disease and further distinguishes severe isolated lesions, which is essential because associated genetic or extracardiac anomalies can alter prognosis dramatically. Isolated CHD is one thing; CHD embedded in a broader syndrome is another. The survival advantage in isolated disease is exactly what one would expect when the heart lesion is the dominant clinical problem rather than one component of a multisystem disorder.
The registry signals progress, but not a cure for prognostic uncertainty
One-year survival of 95.0% in isolated CHD is encouraging, yet the severe isolated subgroup still reminds clinicians how fragile early life can be when cardiac anatomy is profoundly abnormal. A child with critical CHD may require delivery timing, transport logistics, prostaglandin infusion, urgent echocardiography, and rapid surgical decision-making within hours of birth. Improved registry survival reflects not just surgery, but the entire chain of care that begins before delivery and extends through neonatal stabilization.
The change in slope around 2007–2009 deserves attention because it suggests diminishing marginal returns. Early gains may have come from correcting the most immediately lethal bottlenecks: delayed diagnosis, unstable transport, and limited procedural options. Later gains are harder because they depend on reducing complications in patients who were already reaching the system. In congenital cardiology, the remaining deaths tend to cluster in the sickest infants, the most complex anatomies, and the most vulnerable perioperative periods.
One point remains anchored in the data: survival improved alongside declining termination rates in prenatally diagnosed isolated and severe isolated CHD. That pairing suggests the field is changing not only in what it can repair after birth, but also in how prognosis is communicated before birth. The study cannot answer which component mattered most, and it does not separate surgical advances from prenatal detection, but the registry makes one fact clear. Children with congenital heart defects have fared better over the last 30 years, even as the pace of improvement has become less dramatic than before.